Clinical Trial Update: Autogenous Mesenchymal Stem Cell Culture-Derived Signalling Molecules as Enhancers of Bone Formation in Bone Grafting [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating autogenous mesenchymal stem cell culture-derived signalling molecules as enhancers of bone formation in bone grafting; the…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alveolar Bone Atrophy
• Alveolar Bone Loss

Drugs mentioned

• Autogenous Mesenchymal Stem Cell Culture-Derived Signalling Molecules

Snippet

Sponsor: Pontificia Universidade Católica do Rio Grande do Sul | Conditions: Bone Loss, Osteoclastic, Bone Loss, Alveolar | Phase 1, Phase 2 | Status: NOT_YET_RECRUITING